Qianhong Bio-pharma(SZ:002550) Zheng Quan Zhi Xing·2025-06-25 16:36Core Viewpoint - The announcement details the completion and termination of the 2022 Employee Stock Ownership Plan (ESOP) of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd, highlighting the acquisition of shares by the company's general manager and board member Wang Ke, reflecting confidence in the company's future development [1][5]. Group 1: Share Acquisition Details - Wang Ke acquired 22 million shares through block trading, representing 1.72% of the company's total share capital [3][4]. - Prior to the acquisition, Wang Ke held 63,409,600 shares, which was 4.95% of the total share capital [2][4]. - After the acquisition, Wang Ke's total shareholding increased to 85,409,600 shares, or 6.67% of the total share capital [4]. Group 2: Employee Stock Ownership Plan - The 2022 ESOP was approved in August 2022, with 30 million shares transferred to the plan's dedicated account at a price of 4.83 yuan per share, totaling 144.9 million yuan [5][6]. - The lock-up period for the ESOP ended on September 5, 2023, and the plan was extended for an additional 12 months in August 2024 [6]. - As of June 25, 2025, all shares held under the ESOP were sold, with 22 million shares sold to Wang Ke and the remaining 8 million shares sold through centralized bidding [6][7]. Group 3: Compliance and Governance - The share acquisition complies with relevant laws and regulations, ensuring that the company's shareholding structure remains within listing requirements [4][6]. - The acquisition is expected to enhance the company's governance structure and stabilize management control, reflecting the management's confidence in the company's long-term value [4][6].